Sally Susman's most recent trade in UL Solutions Inc - Ordinary Shares - Class A was a trade of 9 Deferred Restricted Stock Unit done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 9 | 4,936 | - | - | Deferred Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 5 | 2,792 | - | - | Deferred Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 2,787 | 2,787 | - | - | Deferred Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 12 | 49 | - | - | Dividend Equivalent Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 156,992 | 156,992 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.31 per share. | 27 Feb 2025 | 85,182 | 250,866 (0%) | 0% | 31.3 | 2,667,048 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 85,182 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.06 per share. | 27 Feb 2025 | 79,779 | 168,909 (0%) | 0% | 26.1 | 2,079,041 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 27 Feb 2025 | 2,178 | 248,688 (0%) | 0% | 26.1 | 56,846 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 22 Feb 2025 | 63,573 | 225,184 (0%) | 0% | 30.2 | 1,917,997 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 63,573 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.08 per share. | 22 Feb 2025 | 56,715 | 165,684 (0%) | 0% | 26.1 | 1,479,127 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.30 per share. | 22 Feb 2025 | 2,785 | 222,399 (0%) | 0% | 26.3 | 73,246 | Common Stock |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 11 | 37 | - | - | Dividend Equivalent Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 43,624 | 43,624 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 43,624 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 40,151 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 40,151 | 40,151 | - | - | Stock Appreciation Rights | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2024 | 12 | 26 | - | - | Dividend Equivalent Rights | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 14 | 14 | - | - | Dividend Equivalent Rights | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,878 | 4,878 | - | - | Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 4,878 | 4,878 | - | - | Deferred Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 4,881 | 4,881 | - | - | Restricted Stock Unit | |
| UL Solutions Inc - Ordinar... | Sally Susman | Director | Purchase of securities on an exchange or from another person at price $ 28.00 per share. | 16 Apr 2024 | 3,571 | 3,571 | - | 28 | 99,988 | Class A Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 68,045 | 68,045 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 60,124 | 60,124 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Susman Sally | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 63,837 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Susman Sally | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.34 per share. | 23 Feb 2024 | 63,837 | 218,148 (0%) | 0% | 27.3 | 1,745,304 | Common Stock |
| Pfizer Inc. | Susman Sally | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.37 per share. | 23 Feb 2024 | 51,589 | 161,611 (0%) | 0% | 27.4 | 1,411,991 | Common Stock |
| Pfizer Inc. | Susman Sally | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.76 per share. | 23 Feb 2024 | 4,948 | 213,200 (0%) | 0% | 27.8 | 137,356 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.89 per share. | 25 Feb 2023 | 72,984 | 209,179 (0%) | 0% | 22.9 | 1,670,604 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 72,984 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.44 per share. | 25 Feb 2023 | 32,455 | 154,311 (0%) | 0% | 43.4 | 1,409,845 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.75 per share. | 25 Feb 2023 | 22,413 | 186,766 (0%) | 0% | 41.8 | 935,743 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 22 Feb 2023 | 76,043 | 195,493 (0%) | 0% | 30.2 | 2,294,217 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2023 | 76,043 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.70 per share. | 22 Feb 2023 | 46,291 | 136,195 (0%) | 0% | 43.7 | 2,022,917 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 43,624 | 43,624 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 37,966 | 37,966 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.38 per share. | 22 Feb 2023 | 13,007 | 182,486 (0%) | 0% | 42.4 | 551,237 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Gift of securities by or to the insider at price $ 0.00 per share. | 11 May 2022 | 5,000 | 119,450 (0%) | 0% | 0 | Common Stock | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.60 per share. | 26 Feb 2022 | 63,580 | 172,880 (0%) | 0% | 25.6 | 1,627,648 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2022 | 63,580 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2022 | 58,623 | 80,225 | - | - | Phantom Stock Units | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.64 per share. | 26 Feb 2022 | 29,685 | 124,450 (0%) | 0% | 50.6 | 1,503,248 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. | 26 Feb 2022 | 18,745 | 154,135 (0%) | 0% | 47.7 | 894,511 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.34 per share. | 23 Feb 2022 | 76,895 | 166,470 (0%) | 0% | 27.3 | 2,102,309 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2022 | 76,895 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 40,151 | 40,151 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.28 per share. | 23 Feb 2022 | 38,060 | 109,300 (0%) | 0% | 51.3 | 1,951,717 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 35,313 | 35,313 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.87 per share. | 23 Feb 2022 | 19,110 | 147,360 (0%) | 0% | 46.9 | 895,686 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.44 per share. | 26 Nov 2021 | 20,520 | 89,575 (0%) | 0% | 54.4 | 1,117,109 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.64 per share. | 26 Nov 2021 | 12,370 | 110,095 (0%) | 0% | 54.6 | 675,897 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.55 per share. | 26 Nov 2021 | 3,700 | 122,465 (0%) | 0% | 54.6 | 201,835 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.45 per share. | 26 Nov 2021 | 2,279 | 126,165 (0%) | 0% | 54.5 | 124,092 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.65 per share. | 26 Nov 2021 | 1,130 | 128,444 (0%) | 0% | 54.7 | 61,755 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.56 per share. | 26 Nov 2021 | 901 | 129,574 (0%) | 0% | 54.6 | 49,159 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.47 per share. | 26 Nov 2021 | 800 | 130,475 (0%) | 0% | 54.5 | 43,576 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.49 per share. | 26 Nov 2021 | 700 | 131,275 (0%) | 0% | 54.5 | 38,143 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.50 per share. | 26 Nov 2021 | 700 | 131,975 (0%) | 0% | 54.5 | 38,150 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.51 per share. | 26 Nov 2021 | 400 | 132,675 (0%) | 0% | 54.5 | 21,804 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.53 per share. | 26 Nov 2021 | 399 | 133,075 (0%) | 0% | 54.5 | 21,757 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.57 per share. | 26 Nov 2021 | 250 | 133,474 (0%) | 0% | 54.6 | 13,643 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.48 per share. | 26 Nov 2021 | 101 | 133,724 (0%) | 0% | 54.5 | 5,502 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 54.43 per share. | 26 Nov 2021 | 58 | 133,825 (0%) | 0% | 54.4 | 3,157 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2021 | 71,899 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.35 per share. | 27 Feb 2021 | 71,899 | 193,474 (0%) | 0% | 22.4 | 1,606,943 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.64 per share. | 27 Feb 2021 | 45,587 | 133,883 (0%) | 0% | 34.6 | 1,579,134 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.49 per share. | 27 Feb 2021 | 14,004 | 179,470 (0%) | 0% | 33.5 | 468,994 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.89 per share. | 25 Feb 2021 | 81,667 | 189,763 (0%) | 0% | 22.9 | 1,869,358 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 81,667 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 66,721 | 66,721 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 57,649 | 57,649 | - | - | Stock Appreciation Rights | |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 25 Feb 2021 | 52,853 | 121,575 (0%) | 0% | 34.8 | 1,837,170 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.82 per share. | 25 Feb 2021 | 15,335 | 174,428 (0%) | 0% | 33.8 | 518,630 | Common Stock |
| Pfizer Inc. | Sally Susman | Executive Vice President | Sale of securities on an exchange or to another person at price $ 41.94 per share. | 09 Nov 2020 | 43,662 | 108,096 (0%) | 0% | 41.9 | 1,831,184 | Common Stock |